Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®

Summary

This is a single center, randomized, blind, parallel controlled clinical trial. The primary objective is to evaluate the single dose pharmacokinetics of recombinant Humanized anti-HER-2 monoclonal antibody injection GB221 in comparison with Herceptin ® in Chinese healthy adult volunteers. The main aim is to study the pharmacokinetic similarity between GB221 and Herceptin ®.

Timeline

Start

2019-11-13

Primary completion

2020-09-08

Completion

2020-09-11

Drugs

Indications